PL90028B1 - - Google Patents
Download PDFInfo
- Publication number
- PL90028B1 PL90028B1 PL1970173769A PL17376970A PL90028B1 PL 90028 B1 PL90028 B1 PL 90028B1 PL 1970173769 A PL1970173769 A PL 1970173769A PL 17376970 A PL17376970 A PL 17376970A PL 90028 B1 PL90028 B1 PL 90028B1
- Authority
- PL
- Poland
- Prior art keywords
- formula
- group
- carbon atoms
- hydrogen
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- -1 nitrilealkyloxy Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 150000002825 nitriles Chemical class 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003672 ureas Chemical class 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000002560 nitrile group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 238000000197 pyrolysis Methods 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- MFEDKMBNKNOUPA-UHFFFAOYSA-N (2-bromo-4,7-dimethyl-3-oxo-7-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(C)C(=O)C(Br)C1C2(CS(O)(=O)=O)C MFEDKMBNKNOUPA-UHFFFAOYSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- CGQOPXGRMLARMJ-UHFFFAOYSA-N 1-(2-chloro-5-methylphenoxy)-3-[(1-methylcyclopentyl)amino]propan-2-ol hydrochloride Chemical compound Cl.ClC1=C(OCC(CNC2(CCCC2)C)O)C=C(C=C1)C CGQOPXGRMLARMJ-UHFFFAOYSA-N 0.000 description 1
- ISRQTIXRVQQREA-UHFFFAOYSA-N 1-amino-1-(2-bromophenoxy)-3-(1-methylcycloheptyl)propan-2-ol Chemical compound BrC1=C(OC(C(CC2(CCCCCC2)C)O)N)C=CC=C1 ISRQTIXRVQQREA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FJRYUYOWGGVHLU-UHFFFAOYSA-N C(#C)C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 Chemical compound C(#C)C1=C(OC(C(CC2(CCCC2)C)O)N)C=CC=C1 FJRYUYOWGGVHLU-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04H—BUILDINGS OR LIKE STRUCTURES FOR PARTICULAR PURPOSES; SWIMMING OR SPLASH BATHS OR POOLS; MASTS; FENCING; TENTS OR CANOPIES, IN GENERAL
- E04H13/00—Monuments; Tombs; Burial vaults; Columbaria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Architecture (AREA)
- Structural Engineering (AREA)
- Civil Engineering (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Przedmiotem wynalazku jest sposób wytwarzania nowych, racemicznych lub optycznie czynnych, 1-feno- ksy-2-iydroksy-3-cyi Nowym zwiazkom odpowiada wzór 1, w którym R oznacza grupe alkilowa, zawierajaca do 5 atomów wegla, Rj oznacza grupe nitrylowa (—C=N), grupe nitrylowa lub trójfluorometylowa albo grupe alkilowa, alkenylowa, alkinylowa, alkoksylowa, alkenyloksylowa, alkinyloksylowa, alkoksyalkilowa, aminoalkilowa, alkilo- aminoalkilowa, dwualkiloaminoalkilowa, alkiloaminowa, dwualkiloaminowa, nitryloalkilowa, alkoksykarbony- lowa, alkiloaminokarbonylowa, alkilotio, acylowa, acyloksylowa lub acyloaminowa, zawierajaca do 5 atomów wegla, grupe aryIowa, aralkilowa, aryloksylowa, lub aryloaminowa, zawierajaca do 10 atomów wegla lub chlorowiec, R2 oznacza wodór, chlorowiec, grupe nitrylowa lub grupe alkilowa albo alkenylowa, zawierajaca do atomów wegla lub razem z Rj oznacza grupe 3,4-metylenodwuoksylowa, bez dalszych podstawników, R3 oznacza wodór, chlorowiec, grupe alkilowa lub alkoksylowa, zawierajaca do 5 atomów wegla i n oznacza liczbe calkowita 2—7.Wedlug wynalazku nowe zwiazki, wytwarza sie przez pirolize pochodnej mocznika o wzorze 2, w którym R4 i R5 moga byc takie same lub rózne i oznaczaja wodór lub grupe alkilowa, zwlaszcza nizsza grupe alkilowa, grupe aralkilowa, zwlaszcza benzylowa lub grupe arylowa, zwlaszcza fenylowa, a R, Ri—R3 i n maja wyzej podane znaczenie.Stosowane jako produkty wyjsciowe pochodne mocznika o wzorze 2 mozna otrzymac, np. metoda opisana w Chem.Abstr. 58/str. 33337 c, polegajaca na reakcji odpowiedniego epoksydu z odpowiednia pochodna mocz¬ nika.Zwiazki otrzymywane sposobem wedlug wynalazku posiadaja asymetryczny atom wegla w grupie CHOH i moga wskutek tego wystepowac jako racematy oraz w postaci optycznych antypodów. Te ostatnie mozna otrzymywac przez rozdzielenie racematu za pomoca zwykle uzywanych kwasów pomocniczych, takich jak kwas dwubenzoilo-D-winowy lub D-3-bromokamforo-8-sulfonowy oraz przez stosowanie optycznie czynnych produk¬ tów wyjsciowych.Otrzymywane sposobem wedlug wynalazku 1-fenoksy-3-cykloalkiloaminopropanole o wzorze 1 mozna2 90028 w znany sposób przeprowadzic w ich fizjologicznie dopuszczalne sole addycyjne z kwasami. Odpowiednimi kwasami sa, np. kwas solny, kwas bromowodorowy, kwas siarkowy, kwas metanosulfonowy, kwas maleinowy, kwas octowy, kwas szczawiowy, kwas mlekowy, kwas winowy lub 8-chloroteofilina.Zwiazki o wzorze 1 wzglednie ich fizjologicznie dopuszczalne sole addycyjne z kwasami wykazuja w badaniach na swinkach morskich, jako zwierzetach doswiadczalnych, wartosciowe wlasciwosci terapeutyczne, w szczególnosci dzialanie 0-adrenol ityczne i mozna je wskutek tego stosowac do leczenia i profilaktyki schorzen naczyn wiencowych serca i arytmii serca, w szczególnosci tychocardii, w medycynie. Równiez dzialanie obniza¬ jace cisnienie krwi powoduje, ze zwiazki te sa interesujace pod wzgledem terapeutycznym.Szczególnie wartosciowymi okazaly sie przy tym takie zwiazki o wzorze 1, w którym R oznacza grupe metylowa, R2 i R3 oznacza zwlaszcza wodór, dalej równiez grupe alkilowa, a Rt oznacza zwlaszcza nienasycona grupe, taka jak grupa etynylowa, nitrylowa, allilowa lub alliloksylowa, w szczególnosci w polozeniu 2 lancucha propanolowego, a n oznacza 4,5 lub 6. Równiez, gdy R oznacza grupe metylowa, Ri oznacza chlorowiec i R2 oznacza wodór wzglednie grupe metylowa i R3 oznacza wodór, a n = 4,5 lub 6, zwiazki odznaczaja sie silnym dzialaniem j3-adreno I itycznym. Szczególnie wartosciowymi pod wzgledem terapeutycznym sa:' 1-(2-etynylofenoksy)-2-hydroksy-3-(1-metylocyklopentylo)-aminopropan, T-(2-nitrylofenoksy)-2-hydroksy-3-(1-metylocyklopentylo)-aminopropan, oraz 1 (2-nitrylofenoksy)-2-hydroksy-3-( 1 -metylocykloheksylo)-aminopropan, 1-(2-chloro-5-metylofenoksy)-2-hy;dr0k$y-3-(1rmety|ocyklopentylo)-aminopronaq i ** 1-(2-bromofenoksy)-2-hydroksy-3-(1-metylocykloheptylo)-aminopropan wzglednie fizjologicznie dopuszczalne sole addycyjne tych zwiazków. 1-(2-nitrylofenoksy)-2-hydroksy-3-(1-metylocyklopentylo)-aminopropan jest szczególnie interesujacym pod wzgledem terapeutycznym z powodu swego wysokiego dzialania antagonistycznego wobec izoproterenolu, przy prawie zupelnym braku wlasnego dzialania powodujacego rzadkoskurcz. Szczególnie aktywnymi sa równiez zwiazki, w których grupa fenyIowa jest podstawiona grupa nitrylowa w polozeniu 2 i równoczesnie nizsza grupe alkilowa, zwlaszcza metylowa w polozeniu 5, np. 1-(2-nitrylo-5-metylofenoksy)-2-hy* droksy-3-(1-metylocyklopentyloamino)-propan, 1-(2-nitrVlo-5-rnetylofenoksy)-2-hydroksy?3-(T-metVl0feykloWe- ksyloamino)-propan i 1-(2-nitrylo-5-metylofenoksy)-2"hydroksy-3-(1-metylocykloheptyloamino)-propan wzgled¬ nie ich fizjologicznie dopuszczalne sole addycyjne z kwasami.Dawka jednostkowa zwiazków otrzymywanych sposobem wedlug wynalazku wynosi 1—300 mg, zwlaszcza —100 mg (doustnie) lub 1—20 mg (pozajelitowo).Galenowa obróbke zwiazków, otrzymywanych sposobem wedlug wynalazku, do zwykle stosowanych form uzytkowych, takich jak roztwory, emulsje, tabletki, drazetki lub preparaty o przedluzonym dzialaniu, przepro¬ wadza sie w znany sposób stosujac zwykle galenowe srodki pomocnicze, nosniki, srodki rozkruszajace, wiazace lub poslizgowe, substancje smakowe, slodzace, srodki do wywolywania przedluzonego dzialania lub ulatwiania rozpuszczania. Zwiazki otrzymywane sposobem wedlug wynalazku mozna równiez laczyc z innymi substancjami o dzialaniu farmakodynamicznymi, takimi jak, np. zwiazki rozszerzajace naczynia wiencowe, sympatykomtme- tyki, glikozydy nasercowe lub srodki uspokajajace.Przyklad. Chlorowodorek 1 (2-chloro-5-metylofenoksy)-2-hydroksy-3-(1 -metylocyklopentyloamino)- propanu. 1,9 g (0,005 mola) N-izopropy1o-N'-(1-metylocyklopentylo)-N'-[2-hydroksy-3-(2-chloro-5- metylofenok- sy)-propylo]-mocznika, 15 ml tetraliny i 100 mg LiCI laczy sie i ogrzewa przez 1 godzine do temperatury 200°C.Calosc zadaje sie eterem i 2 razy wytrzasa z 1n HCI, stosujac kazdorazowo po 10 ml. Polaczone fazy HCI przemywa sie mala iloscia eteru i alkalizuje za pomoca NaOH. Wytracajacy sie olej rozpuszcza sie w eterze.Po przemyciu woda i wysuszeniu nad MgS04 eter oddestylowuje sie. Pozostaly olej rozpuszcza sie w etanolu i zakwasza alkoholowym roztworem HCI. Po zadaniu eterem krystalizuje chlorowodorek. Temperatura topnienia: 170—172°C, wydajnosc: 600 mg.Sposobem opisanym w podanym przykladzie wytwarza sie nastepujace zwiazki o wzorze 1:90028 3 , Temperaturatopnienia Rj R2 R3 R4 R w°C (chlorowodorek) 1 2-CN 2-CN 2-Br 2-Br 2-CH2C=CH 2-CH2CH= 2-C=CH 2-Br 2-C1 2-C1 2-CN =CH3 2-CH2OCH 2-CH2CH= 2-CH=CH 2-CH3 2-CN 2-C1 2-CN =CH2 2-CH2C^CH 2-CH2CH= 2-CH2CH= 2-CH2CH- 2-CN 2-CN 2-CN 2-CN =CH2 =CH2 *CH2 H H H H H H H H - - H H H H 4- H - H H H H H 4- - - 2 CH3 CH3 ¦CN CH3 Cl CH3 CH3 -CH3 3 H H H H H H H H H H H H H H H H H H H H H H K.H H H 4 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 C2H5 C2H5 CH3 CH3 CH3 CH3 i-C3H7 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 4 4 4 6 4 4 6 6 6 6 4 6 4 6 163 - 165 132-134 156-157 157-158 137-138 141-143 (szczawian) 171-173 167-168 174-177 179-180 157-158 167-168 110-111 184-185 206-207 200-201 191-194 160-161 110-111 124-126 97- 99 100-101 (szczawian) 194-196 173-176 192-194 143-146 PL PL PL PL PL PL
Claims (2)
1. Za st r z ez e n i a pa t e n to we 1. Sposób wytwarzania nowych 1-fenoksy-2-hydroksy-3-cykloalkiloaminopropanów o wzorze 1, w którym R oznacza grupe alkilowa, zawierajaca do 5 atomów wegla, Ri oznacza grupe nitrylowa, nitrylowa, lub trójfluorometylowa lub grupe alkilowa, alkenylowa, alkinylowa, alkoksyIowa, alkenyloksylowa, alkinyloksylowa, alkoksyalkilowa, aminoalkilowa, alkiloaminoalkilowa, dwualkiloaminoalkilowa, alkiloaminowa, dwualkiloami- nowa, nitryloalkilowa, alkoksykarbonyIowa, alkiloaminokarbonylowa, alkilotio, acylowa, acyloksylowa lub acyloaminowa, zawierajaca do 5 atomów wegla, grupe arylowa, aralkilowa, aryloksylowa, aralkoksylowa lub aryloaminowa, zawierajaca do 10 atomów wegla lub chlorowiec, R2 oznacza wodór, chlorowiec, grupe nitrylowa lub grupe alkilowa, a Ikoksy Iowa lub alkenylowa, zawierajaca do 5 atomów wegla, R3 oznacza wodór, chlorowiec, grupe alkilowa lub a I koksyIowa, zawierajaca do 5 atomów wegla lub Ri i R2 razem oznaczaja grupe 3,4-metylenodwuoksylowa, przy czym w tym przypadku R3 oznacza wodór i n oznacza liczbe calkowita 2—7 w postaci racematu lub izomerów optycznie czynnych oraz ich fizjologicznie dopuszczalnych soli addycyjnych z kwasami, znamienny tym, ze pochodna mocznika o wzorze 2, w którym R4 i R5 sa takie same lub rózne i oznaczaja wodór lub grupe alkilowa, aralkilowa lub arylowa, a R, Ri—R3 in maja wyzej podane znaczenie, poddaje sie pirolizie i otrzymany zwiazek o wzorze 1, o ile wystepuje w postaci racematu ewentualnie przeprowadza za pomoca kwasów pomocniczych w jego diastereomeryczne sole, które rozdziela sie przez frakcjonowana krystalizacje i zwiazki, o wzorze 1 ewentualnie przeprowadza w fizjologicznie dopuszczalne sole addycyjne z kwasami.
2. Sposób wedlug zastrz. 1, znamienny tym, ze stosuje sie zwiazek o wzorze 2, w którym R4 i R5 oznaczaja nizsza grupe alkilowa, grupe benzylowa lub fenylowa.90 028 <^^^0CHrCH0H-CHrNH-c3H2)n 2 R3 * WZCJR 1 0 f l'V0CHrCH0H-CHrN-C-NR4R5 0»Un R WZÓR 2 Prac. Poligraf. UP PRL naklad 120+18 Cena 10 zl PL PL PL PL PL PL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1937477A DE1937477C3 (de) | 1969-07-23 | 1969-07-23 | I -Phenoxy-2-hydroxy-3-(l -methylcycloalkylamino)-propane, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL90028B1 true PL90028B1 (pl) | 1976-12-31 |
Family
ID=5740681
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173770A PL90027B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173768A PL90029B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173769A PL90028B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173765A PL90039B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173767A PL90030B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173771A PL90026B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173772A PL90025B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970142196A PL79772B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173766A PL90038B1 (pl) | 1969-07-23 | 1970-07-21 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173770A PL90027B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173768A PL90029B1 (pl) | 1969-07-23 | 1970-07-21 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1970173765A PL90039B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173767A PL90030B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173771A PL90026B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173772A PL90025B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970142196A PL79772B1 (pl) | 1969-07-23 | 1970-07-21 | |
| PL1970173766A PL90038B1 (pl) | 1969-07-23 | 1970-07-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3755413A (pl) |
| JP (5) | JPS5133106B1 (pl) |
| AT (9) | AT304475B (pl) |
| BE (1) | BE753774A (pl) |
| BG (9) | BG17508A3 (pl) |
| CH (10) | CH550140A (pl) |
| CS (9) | CS170528B2 (pl) |
| DE (1) | DE1937477C3 (pl) |
| DK (1) | DK140281B (pl) |
| ES (8) | ES382014A1 (pl) |
| FR (1) | FR2059551B1 (pl) |
| GB (1) | GB1314896A (pl) |
| NL (1) | NL169874C (pl) |
| PL (9) | PL90027B1 (pl) |
| RO (9) | RO59210A (pl) |
| SE (1) | SE370391B (pl) |
| YU (5) | YU34395B (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021576A (en) * | 1969-07-23 | 1977-05-03 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing a 1-(2'-ethynyl-phenoxy)-2-hydroxy-3-(cycloalkyl-amino)-propane and method of use |
| US3937706A (en) * | 1969-07-23 | 1976-02-10 | Boehringer Ingelheim Gmbh | 1-(2'ethynyl-phenoxy)-2-hydroxy-3-(cycloalkyl-amino)-propanes and salts thereof |
| US4038313A (en) * | 1970-01-08 | 1977-07-26 | Ciba-Geigy Corporation | Cycloalkylureido phenoxy propanolamines |
| US4120978A (en) * | 1970-01-08 | 1978-10-17 | Ciba-Geigy Corporation | Pharmaceutical composition for inhibiting and blocking cardioselective beta-receptors |
| SE354851B (pl) * | 1970-02-18 | 1973-03-26 | Haessle Ab | |
| US4145442A (en) * | 1972-04-04 | 1979-03-20 | Aktiebolaget Hassle | Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases |
| US4038414A (en) * | 1972-06-08 | 1977-07-26 | Ciba-Geigy Corporation | Amines and processes for their manufacture |
| US4035420A (en) * | 1972-07-06 | 1977-07-12 | Aktiebolaget Hassle | Substituted ureido alkylene phenoxy propanolamines |
| DE2309887C2 (de) * | 1973-02-28 | 1983-11-10 | C.H. Boehringer Sohn, 6507 Ingelheim | 1-Aryloxy-2-hydroxy-3-alkinylaminopropan-Derivate und deren physiologisch verträgliche Säureadditionssalze, pharmazeutische Präparate und Herstellungsverfahren für die Verbindungen |
| US4220659A (en) * | 1974-02-22 | 1980-09-02 | Boehringer Ingelheim Gmbh | 1-Phenoxy-2-hydroxy-3-alkynylamino-propanes and salts thereof |
| DK405775A (da) * | 1974-09-12 | 1976-03-13 | American Cyanamid Co | Fremgangsmade til fremstilling af alkanolaminer |
| US4165384A (en) * | 1974-11-01 | 1979-08-21 | Aktiebolaget Hassle | Amide substituted phenoxy propanol amines |
| US4387103A (en) * | 1980-11-28 | 1983-06-07 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
| US4471127A (en) * | 1981-09-08 | 1984-09-11 | Ciba-Geigy Corporation | 1-5-Bis-(1,4-benzodioxin-2-yl)-3-azapentane-1,5-diols |
| US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
| JPS6364630U (pl) * | 1986-10-17 | 1988-04-28 |
-
1969
- 1969-07-23 DE DE1937477A patent/DE1937477C3/de not_active Expired
-
1970
- 1970-03-22 BG BG017138A patent/BG17508A3/xx unknown
- 1970-03-23 BG BG017134A patent/BG17750A3/xx unknown
- 1970-07-16 CH CH224473A patent/CH550140A/xx not_active IP Right Cessation
- 1970-07-16 CH CH1106675A patent/CH575376A5/xx not_active IP Right Cessation
- 1970-07-16 CH CH224773A patent/CH536812A/de not_active IP Right Cessation
- 1970-07-16 CH CH224273A patent/CH536809A/de not_active IP Right Cessation
- 1970-07-16 CH CH224973A patent/CH550139A/xx not_active IP Right Cessation
- 1970-07-16 CH CH224573A patent/CH536810A/de not_active IP Right Cessation
- 1970-07-16 CH CH1087370A patent/CH537360A/de not_active IP Right Cessation
- 1970-07-16 CH CH224673A patent/CH536811A/de not_active IP Right Cessation
- 1970-07-16 CH CH224873A patent/CH536813A/de not_active IP Right Cessation
- 1970-07-16 CH CH224373A patent/CH570363A5/xx not_active IP Right Cessation
- 1970-07-20 RO RO69805A patent/RO59210A/ro unknown
- 1970-07-20 RO RO63988A patent/RO56318A/ro unknown
- 1970-07-20 RO RO69801A patent/RO59112A/ro unknown
- 1970-07-20 RO RO69806A patent/RO59211A/ro unknown
- 1970-07-20 RO RO69802A patent/RO59089A/ro unknown
- 1970-07-20 RO RO69799A patent/RO60112A/ro unknown
- 1970-07-20 RO RO69804A patent/RO59209A/ro unknown
- 1970-07-20 RO RO69803A patent/RO59159A/ro unknown
- 1970-07-20 RO RO69798A patent/RO60111A/ro unknown
- 1970-07-21 CS CS4505A patent/CS170528B2/cs unknown
- 1970-07-21 PL PL1970173770A patent/PL90027B1/pl unknown
- 1970-07-21 CS CS4508A patent/CS170531B2/cs unknown
- 1970-07-21 PL PL1970173768A patent/PL90029B1/pl unknown
- 1970-07-21 PL PL1970173769A patent/PL90028B1/pl unknown
- 1970-07-21 GB GB3535970A patent/GB1314896A/en not_active Expired
- 1970-07-21 PL PL1970173765A patent/PL90039B1/pl unknown
- 1970-07-21 PL PL1970173767A patent/PL90030B1/pl unknown
- 1970-07-21 PL PL1970173771A patent/PL90026B1/pl unknown
- 1970-07-21 ES ES382014A patent/ES382014A1/es not_active Expired
- 1970-07-21 PL PL1970173772A patent/PL90025B1/pl unknown
- 1970-07-21 CS CS4503A patent/CS170526B2/cs unknown
- 1970-07-21 CS CS4506A patent/CS170529B2/cs unknown
- 1970-07-21 CS CS4502A patent/CS170525B2/cs unknown
- 1970-07-21 CS CS5136A patent/CS170524B2/cs unknown
- 1970-07-21 CS CS4509A patent/CS170532B2/cs unknown
- 1970-07-21 PL PL1970142196A patent/PL79772B1/pl unknown
- 1970-07-21 CS CS4507A patent/CS170530B2/cs unknown
- 1970-07-21 CS CS4504A patent/CS170527B2/cs unknown
- 1970-07-21 PL PL1970173766A patent/PL90038B1/pl unknown
- 1970-07-22 BG BG017135A patent/BG17751A3/xx unknown
- 1970-07-22 BG BG015254A patent/BG17749A3/xx unknown
- 1970-07-22 BG BG018645A patent/BG19132A3/xx unknown
- 1970-07-22 BG BG017137A patent/BG18852A3/xx unknown
- 1970-07-22 DK DK380170AA patent/DK140281B/da unknown
- 1970-07-22 YU YU1860/70A patent/YU34395B/xx unknown
- 1970-07-22 JP JP45063634A patent/JPS5133106B1/ja active Pending
- 1970-07-22 BG BG017136A patent/BG17507A3/xx unknown
- 1970-07-22 BE BE753774D patent/BE753774A/xx not_active IP Right Cessation
- 1970-07-22 US US00057353A patent/US3755413A/en not_active Expired - Lifetime
- 1970-07-23 AT AT118272A patent/AT304475B/de active
- 1970-07-23 SE SE7010200A patent/SE370391B/xx unknown
- 1970-07-23 AT AT118472A patent/AT304477B/de not_active IP Right Cessation
- 1970-07-23 AT AT674870A patent/AT303706B/de not_active IP Right Cessation
- 1970-07-23 FR FR7027291A patent/FR2059551B1/fr not_active Expired
- 1970-07-23 AT AT118072A patent/AT306703B/de not_active IP Right Cessation
- 1970-07-23 AT AT118172A patent/AT304474B/de active
- 1970-07-23 NL NLAANVRAGE7010928,A patent/NL169874C/xx not_active IP Right Cessation
- 1970-07-23 AT AT117972A patent/AT306702B/de not_active IP Right Cessation
- 1970-07-23 AT AT118572A patent/AT304478B/de active
- 1970-07-23 AT AT118372A patent/AT304476B/de not_active IP Right Cessation
- 1970-07-23 AT AT118672A patent/AT306704B/de not_active IP Right Cessation
- 1970-07-24 BG BG017133A patent/BG17506A3/xx unknown
- 1970-07-24 BG BG017132A patent/BG17505A3/xx unknown
-
1971
- 1971-09-09 ES ES394918A patent/ES394918A1/es not_active Expired
- 1971-09-09 ES ES394915A patent/ES394915A1/es not_active Expired
- 1971-09-09 ES ES394919A patent/ES394919A1/es not_active Expired
- 1971-09-09 ES ES394917A patent/ES394917A1/es not_active Expired
- 1971-09-09 ES ES394913A patent/ES394913A1/es not_active Expired
- 1971-09-09 ES ES394914A patent/ES394914A1/es not_active Expired
- 1971-09-09 ES ES394916A patent/ES394916A1/es not_active Expired
-
1973
- 1973-06-06 JP JP48063727A patent/JPS5238556B1/ja active Pending
- 1973-06-06 JP JP48063728A patent/JPS5210861B1/ja active Pending
- 1973-06-06 JP JP48063729A patent/JPS5210862B1/ja active Pending
- 1973-06-06 JP JP48063730A patent/JPS5210863B1/ja active Pending
-
1975
- 1975-10-07 YU YU2545/75A patent/YU34662B/xx unknown
- 1975-10-07 YU YU2544/75A patent/YU34396B/xx unknown
- 1975-10-07 YU YU2551/75A patent/YU34113B/xx unknown
- 1975-10-07 YU YU2546/75A patent/YU34663B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL90028B1 (pl) | ||
| US4711899A (en) | 2-(4-benzoyl-1-piperidyl)-1-phenylalkanol derivatives | |
| US4603204A (en) | Theophylline derivatives | |
| DK160820B (da) | Analogifremgangsmaade til fremstilling af 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinolinderivater | |
| JPS62167752A (ja) | フエニルアセトニトリル誘導体その医薬組成物および哺乳動物におけるカルシウムイオンきつ抗作用または抗高圧作用促進方法 | |
| FI79536C (fi) | Foerfarande foer framstaellning av piperidindionderivat med myokardisk skyddsverkan samt med rytmstoerningar bekaempande verkan. | |
| FR2479825A1 (fr) | Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments | |
| PL91728B1 (pl) | ||
| PL94266B1 (pl) | ||
| FR2557570A1 (fr) | Nouveaux derives de la quinoleine, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| US3989722A (en) | 1-Aminomethyl-2,2-diaryl-cyclopropane carboxamides | |
| EP0015171B1 (fr) | Dérivés condensés de pyrrolidine ou de pipéridine, leur procédé de préparation et composition les contenant | |
| FR2460294A1 (fr) | Nouveaux oxime-ethers, leur procede de preparation et compositions pharmaceutiques les contenant | |
| CS214841B2 (en) | Method of making the tetrahydrochinolines | |
| US5055490A (en) | Stereoisomers of benzonitrile derivatives, useful as cardiac arrhythmiac agents | |
| DK170043B1 (da) | 5-phenyl-1,4,5,6-tetrahydropyrimidinderivater, fremgangsmåde til fremstilling heraf, farmaceutisk middel indeholdende disse samt anvendelse af derivaterne til fremstilling af et farmaceutisk middel | |
| US3960862A (en) | 1,3-Diazacycloalkeno-[1,2,d]-benzo-[f-]-1,3,4-thiadiazepines | |
| EP0107536B1 (fr) | Benzo-et thiéno-triazine-1,2,3 ones-4, procédés de préparation et médicaments les contenant | |
| US3957845A (en) | Trifluoromethyl-substituted phenyl acetonitriles | |
| FR2571965A1 (fr) | Medicaments a base de nouveaux derives de la 4 h-dioxino-(4,5-c)-pyridine. | |
| US4147871A (en) | Cyclohexanetetrol derivatives | |
| EP0106860B1 (fr) | Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant | |
| EP0157762B1 (fr) | Nouvelles piperidinoguanidines substituees, leur procede de preparation et les compositions pharmaceutiques en renfermant | |
| FR2539414A1 (fr) | Derives de la pyrimidine, leur procede de preparation et les medicaments ayant une activite sur le systeme nerveux central qui en contiennent | |
| AT212318B (de) | Verfahren zur Herstellung von neuen Phenthiazinderivaten |